Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 27, 2019

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Acute Myeloid LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Eosinophilic Leukemia, Not Otherwise SpecifiedChronic Myelomonocytic LeukemiaChronic Neutrophilic LeukemiaEssential ThrombocythemiaMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and ThrombocytosisMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiableMyeloid NeoplasmMyeloproliferative NeoplasmMyeloproliferative Neoplasm, UnclassifiableOvert Primary MyelofibrosisPolycythemia VeraPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrefibrotic/Early Primary Myelofibrosis
Interventions
DRUG

Azacitidine

Given IV or SC

DRUG

Pevonedistat

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03862157 - Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter